Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) posted its earnings results on Friday. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.08, Zacks reports. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The firm had revenue of $3.77 billion during the quarter, compared to the consensus estimate of $3.58 billion.
Daiichi Sankyo Price Performance
DSNKY stock opened at $17.44 on Friday. The stock’s 50 day moving average is $17.77 and its two-hundred day moving average is $17.66. Daiichi Sankyo has a 52-week low of $14.98 and a 52-week high of $24.77. The company has a market capitalization of $32.49 billion, a PE ratio of 20.28, a P/E/G ratio of 1.76 and a beta of -0.11. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29.
Analyst Ratings Changes
DSNKY has been the subject of several research reports. Zacks Research downgraded shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Daiichi Sankyo currently has an average rating of “Reduce”.
View Our Latest Stock Analysis on Daiichi Sankyo
Daiichi Sankyo Company Profile
Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.
Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.
See Also
- Five stocks we like better than Daiichi Sankyo
- The Factories Behind AI Servers Just Raised Their Outlooks—3 Contract Manufacturers to Watch
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
